Chantel Kowalchuk1, Celine Teo1, Virginia Wilson1, Araba Chintoh1, Loretta Lam1, Sri Mahavir Agarwal1, Adria Giacca1, Gary J Remington1, Margaret K Hahn1. 1. From the Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kowalchuk, Teo, Wilson, Chintoh, Agarwal, Remington, Hahn); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kowalchuk, Giacca, Remington, Hahn); the Department of Psychiatry, University of Toronto, Toronto, Ont., Canada (Chintoh, Remington, Hahn); and the Department of Physiology, University of Toronto, Toronto, Ont., Canada (Lam, Giacca).
Abstract
BACKGROUND: Insulin receptors are widely expressed in the brain and may represent a crossroad between metabolic and cognitive disorders. Although antipsychotics, such as olanzapine, are the cornerstone treatment for schizophrenia, they are associated with high rates of type 2 diabetes and lack efficacy for illness-related cognitive deficits. Historically, this risk of diabetes was attributed to the weight gain propensity of antipsychotics, but recent work suggests antipsychotics can have weight-independent diabetogenic effects involving unknown brain-mediated mechanisms. Here, we examined whether antipsychotics disrupt central insulin action, hypothesizing that olanzapine would impair the well-established ability of central insulin to supress hepatic glucose production. METHODS: Pancreatic euglycemic clamps were used to measure glucose kinetics alongside a central infusion of insulin or vehicle into the third ventricle. Male rats were pretreated with olanzapine or vehicle per our established model of acute olanzapine-induced peripheral insulin resistance. Groups included (central-peripheral) vehicle-vehicle (n = 11), insulin-vehicle (n = 10), insulin-olanzapine (n = 10) and vehicle-olanzapine (n = 8). RESULTS: There were no differences in peripheral glucose or insulin levels. Unexpectedly, we showed that central insulin increased glucose uptake, and this effect was not perturbed by olanzapine. We replicated suppression of glucose production by insulin (clamp relative to basal: 77.9% ± 13.1%, all p < 0.05), an effect abolished by olanzapine (insulin-olanzapine: 7.7% ± 14%). LIMITATIONS: This study used only male rats and an acute dose of olanzapine. CONCLUSION: To our knowledge, this is the first study suggesting olanzapine may impair central insulin sensing, elucidating a potential mechanism of antipsychotic-induced diabetes and opening avenues of investigation related to domains of schizophrenia psychopathology.
BACKGROUND: Insulin receptors are widely expressed in the brain and may represent a crossroad between metabolic and cognitive disorders. Although antipsychotics, such as olanzapine, are the cornerstone treatment for schizophrenia, they are associated with high rates of type 2 diabetes and lack efficacy for illness-related cognitive deficits. Historically, this risk of diabetes was attributed to the weight gain propensity of antipsychotics, but recent work suggests antipsychotics can have weight-independent diabetogenic effects involving unknown brain-mediated mechanisms. Here, we examined whether antipsychotics disrupt central insulin action, hypothesizing that olanzapine would impair the well-established ability of central insulin to supress hepatic glucose production. METHODS: Pancreatic euglycemic clamps were used to measure glucose kinetics alongside a central infusion of insulin or vehicle into the third ventricle. Male rats were pretreated with olanzapine or vehicle per our established model of acute olanzapine-induced peripheral insulin resistance. Groups included (central-peripheral) vehicle-vehicle (n = 11), insulin-vehicle (n = 10), insulin-olanzapine (n = 10) and vehicle-olanzapine (n = 8). RESULTS: There were no differences in peripheral glucose or insulin levels. Unexpectedly, we showed that central insulin increased glucose uptake, and this effect was not perturbed by olanzapine. We replicated suppression of glucose production by insulin (clamp relative to basal: 77.9% ± 13.1%, all p < 0.05), an effect abolished by olanzapine (insulin-olanzapine: 7.7% ± 14%). LIMITATIONS: This study used only male rats and an acute dose of olanzapine. CONCLUSION: To our knowledge, this is the first study suggesting olanzapine may impair central insulin sensing, elucidating a potential mechanism of antipsychotic-induced diabetes and opening avenues of investigation related to domains of schizophrenia psychopathology.
Authors: R E Nielsen; S Levander; G Kjaersdam Telléus; S O W Jensen; T Østergaard Christensen; S Leucht Journal: Acta Psychiatr Scand Date: 2015-01-16 Impact factor: 6.392
Authors: Karen L Houseknecht; Alan S Robertson; William Zavadoski; E Michael Gibbs; David E Johnson; Hans Rollema Journal: Neuropsychopharmacology Date: 2006-10-11 Impact factor: 7.853
Authors: Anita M van den Hoek; Peter J Voshol; Barbara N Karnekamp; Ruud M Buijs; Johannes A Romijn; Louis M Havekes; Hanno Pijl Journal: Diabetes Date: 2004-10 Impact factor: 9.461
Authors: Araba F Chintoh; Steve W Mann; Loretta Lam; Carol Lam; Tony A Cohn; Paul J Fletcher; Jose N Nobrega; Adria Giacca; Gary Remington Journal: J Clin Psychopharmacol Date: 2008-10 Impact factor: 3.153
Authors: Laura N Castellani; Sandra Pereira; Chantel Kowalchuk; Roshanak Asgariroozbehani; Raghunath Singh; Sally Wu; Laurie Hamel; Khaled Alganem; William G Ryan; Xiaolu Zhang; Emily Au; Araba Chintoh; Gary Remington; Sri Mahavir Agarwal; Adria Giacca; Robert E Mccullumsmith; Margaret K Hahn Journal: Mol Psychiatry Date: 2022-10-14 Impact factor: 13.437
Authors: Jacobi I Cunningham; David J Eyerman; Mark S Todtenkopf; Reginald L Dean; Daniel R Deaver; Connie Sanchez; Mark Namchuk Journal: J Psychopharmacol Date: 2019-07-11 Impact factor: 4.153
Authors: Jessica W Y Yuen; David D Kim; Ric M Procyshyn; William J Panenka; William G Honer; Alasdair M Barr Journal: Front Endocrinol (Lausanne) Date: 2021-02-25 Impact factor: 5.555